RPG Life Sciences to Acquire API Business of Raghava Life Sciences for ₹135 Crore
RPG Life Sciences' subsidiary will acquire the API and intermediates business of Raghava Life Sciences via slump sale for up to ₹135 crore. The acquired business had FY26 revenues of ₹19 crore and includes manufacturing, R&D facilities, and 29 API molecules. This aligns with the company's strategy to expand its API segment.
The acquisition of a business with substantial revenue and assets, along with a significant cash consideration, is expected to have a material impact on RPG Life Sciences' business operations and market position in the pharmaceutical sector.
The acquisition is strategically aligned with the company's growth objectives in the API business and involves a significant investment that is expected to expand its operations and product portfolio.
RPG Life Sciences Limited announced that its wholly owned subsidiary, RPG Active Pharma Limited, will acquire the Active Pharmaceutical Ingredients (APIs) and intermediates business of Raghava Life Sciences Private Limited through a Business Transfer Agreement (BTA) via a slump sale. This strategic move, aimed at expanding the company's API business, involves acquiring a business with FY26 revenues of approximately ₹19 crore, along with manufacturing facilities, an R&D facility, and a portfolio of 29 API molecules.
The total consideration for this acquisition is up to ₹135 crore, subject to customary adjustments and applicable taxes. The transaction does not involve the purchase of shares in any entity. Raghava Life Sciences Private Limited's business being acquired focuses on the development and manufacturing of APIs and intermediates.
The Board of Directors of RPG Life Sciences Limited approved the execution of the BTA during a meeting held on Wednesday, September 02, 2026, which commenced at 7:00 pm and concluded at 8:10 pm. The completion of the transaction is tentatively expected within 30 days, subject to the satisfaction of closing conditions and necessary regulatory approvals.
A plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.